Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
- DOI
- 10.1016/j.esmoop.2021.100113
- Published
- 2021 Jun
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2021.100113,
title = {Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.},
author = {Paz-Ares L and Barlesi F and Siena S and Ahn MJ and Drilon A and Conley A and Rolfo C and Wolf J and Seto T and Doebele R and Kapre A and Chen D and McCallum S and Osborne S and Demetri G},
year = {2021},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2021.100113},
url = {https://doi.org/10.1016/j.esmoop.2021.100113}
}RIS
TY - JOUR TI - Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. AU - Paz-Ares L AU - Barlesi F AU - Siena S AU - Ahn MJ AU - Drilon A AU - Conley A AU - Rolfo C AU - Wolf J AU - Seto T AU - Doebele R AU - Kapre A AU - Chen D AU - McCallum S AU - Osborne S AU - Demetri G PY - 2021 JO - ESMO open DO - 10.1016/j.esmoop.2021.100113 UR - https://doi.org/10.1016/j.esmoop.2021.100113 ER -
APA
L, P., F, B., S, S., MJ, A., A, D., A, C., C, R., J, W., T, S., R, D., A, K., D, C., S, M., S, O., & G, D. (2021). Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.. ESMO open. https://doi.org/10.1016/j.esmoop.2021.100113
Source records
- pubmed · retrieved 2026-09-26T18:43:45.752Z
- europe-pmc · retrieved 2026-09-26T18:43:45.773Z